UCB agrees to acquire Neurona Therapeutics, a Ysios Capital portfolio company, in a deal worth up to $1.15 billion

by Ysios Capital

UCB, a global biopharmaceutical company, has announced that it has entered into a definitive agreement under which UCB would acquire Neurona Therapeutics, an Ysios Capital portfolio company, including...

Read more
Subscribe to Directory
Write an Article

Highlight

Axon moves into Cloud Technology

by Axon Partners Group

cloud technology axon

Decelera strengthens its commitment to e...

by Sancus Capital

These investments reinforce Decelera’s commitment to identifying, su...

Photos Stream